Therapeutics News

NEW YORK — In this presentation from OSN New York, Pete Setabutr, MD, of University of Illinois, Chicago, highlights nontraditional techniques to manage eyelid malposition.

Every year Healio covers a wide range of optometry-related news from the FDA, and 2024 was no exception.

INDIANAPOLIS — A single spray of MydCombi administered via the Optejet dispenser was comparable in efficacy to the label recommendation of two sprays in inducing clinically relevant mydriasis, according to researchers at Academy 2024.

An escalating monotherapy regimen was just as effective as multitherapy for most patients with untreated glaucoma, although those with higher baseline IOP may benefit from more intensive treatment, according to a study conducted in Sweden.

INDIANAPOLIS — Individuals with mild to moderate presbyopia who were treated with CSF-1 were able to achieve and maintain functional vision for at least 5 hours after two doses, according to a presenter at Academy 2024.

Bausch + Lomb has announced that its Soothe antibiotic drops have been approved by Health Canada for over-the-counter use in the treatment of external infections of the eye and ear, according to a company press release.

Glaukos announced that Epioxa, its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, demonstrated statistically significant improvement from baseline vs. placebo in maximum corneal curvature at 12 months.

Filling an opioid prescription after ophthalmic surgery was associated with higher rates of hospitalization, overdose, abuse or dependency, and mortality, according to a study published in Ophthalmology.

Aldeyra Therapeutics has resubmitted a new drug application for topical reproxalap for the treatment of signs and symptoms of dry eye disease, the company announced in a press release.